Project Grant R21CA313180
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. a $398,544 Project Grant (CFDA 93.395: Cancer Treatment Research) effective April 8, 2026, through March 31, 2028, to conduct pre-clinical evaluation of PRT3789, a highly selective SMARCA2 degrader, for treating therapy-resistant triple-negative breast cancer (TNBC). The project addresses a critical clinical gap: patients with residual disease following neoadjuvant...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $399,829 under the Cancer Treatment Research program (CFDA 93.395) to develop next-generation engineered T cells with enhanced persistence for cancer immunotherapy. The award, initiated April 1, 2026 and concluding March 31, 2028, supports research focused on rationally designing chimeric antigen receptor (CAR) T cells that incorporate 4-1BB (CD137) signaling domains to...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded $641,419 to Washington University's Office of Sponsored Research Services on May 7, 2026, for clinical translation research of a novel Meitner-Auger electron (MAE) positron emission tomography (PET) theranostic agent. The project, extending through April 30, 2031, focuses on developing and evaluating [77Br]Br-WC-DZ, a stable bromine-77 ligand targeting...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a Project Grant of $542,644 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The award, effective April 1, 2026 through March 31, 2031, supports research into a transformative therapeutic approach that leverages the discovery of Tax-Interacting Protein 1 (TIP1) as a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- Federal Project Grant Award Summary Mayo Clinic received a $957,572 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) with an award date of May 12, 2026, and a completion date of April 30, 2031. The grant funds basic and translational research investigating ADAR1 (Adenosine Deaminase Acting on RNA 1) as a novel therapeutic target for breast cancer treatment, with particular focus on triple-negative breast cancer (TNBC)....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $155,479 Project Grant effective June 1, 2026 through May 31, 2028 under the Cancer Treatment Research program (CFDA 93.395) to develop and validate an anti-CCRL2 (C-C motif receptor-like 2) antibody-drug conjugate (ADC) targeting high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 mutations. The research addresses a critical clinical need, as patients with...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $518,151 Project Grant to the University of Chicago effective July 1, 2026, through June 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and preclinical advancement of NNMTI'960, a small-molecule inhibitor targeting Nicotinamide N-methyltransferase (NNMT) in the tumor microenvironment. The research investigates how NNMT inhibition reshapes tumor metabolism...